JNJ - 10198409,> = 98 %( HPLC), solide

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

JNJ-10198409 is a potent ATP-competitive inhibitor of Platelet-Derived Growth Factor receptor tyrosine kinase (PDGF-RTK) with both antiangiogenic and a direct tumor cell antiproliferative activity. It is selective for PDGF-β kinase with IC₅₀ values of 4.2 nM for PDGF-β and 45 nM for PDGF-α kinase.

Features and Benefits

This compound is featured on the PAF Receptor and PDGFR pages of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound is a featured product for Kinase Phosphatase Biology research. Click here to discover more featured Kinase Phosphatase Biology products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Packaging

1, 5 mg in glass bottle